Krystal Biotech Stock EBITDA
| KRYS Stock | USD 246.37 3.02 1.21% |
Fundamental analysis of Krystal Biotech allows traders to better anticipate movements in Krystal Biotech's stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| EBITDA | 98.9 M | 103.9 M |
Krystal | EBITDA | Build AI portfolio with Krystal Stock |
Krystal Biotech Company EBITDA Analysis
Krystal Biotech's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Krystal Biotech EBITDA | 109.91 M |
Most of Krystal Biotech's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Krystal Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Krystal EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Krystal Biotech is extremely important. It helps to project a fair market value of Krystal Stock properly, considering its historical fundamentals such as EBITDA. Since Krystal Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Krystal Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Krystal Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Krystal Ebitda
Ebitda |
|
According to the company disclosure, Krystal Biotech reported earnings before interest,tax, depreciation and amortization of 109.91 M. This is 87.47% lower than that of the Biotechnology sector and 9.74% higher than that of the Health Care industry. The ebitda for all United States stocks is 97.18% higher than that of the company.
Krystal EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Krystal Biotech's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics of similar companies.Krystal Biotech is currently under evaluation in ebitda category among its peers.
Krystal Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Krystal Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Krystal Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Krystal Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Krystal Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Krystal Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Krystal Biotech's value.| Shares | Goldman Sachs Group Inc | 2025-06-30 | 530.4 K | Dimensional Fund Advisors, Inc. | 2025-06-30 | 505.9 K | Norges Bank | 2025-06-30 | 282.7 K | T. Rowe Price Associates, Inc. | 2025-06-30 | 261.4 K | Northern Trust Corp | 2025-06-30 | 251.4 K | Charles Schwab Investment Management Inc | 2025-06-30 | 246.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 234.4 K | Ubs Asset Mgmt Americas Inc | 2025-06-30 | 234.3 K | First Trust Advisors L.p. | 2025-06-30 | 222.4 K | Fmr Inc | 2025-06-30 | 4.3 M | Blackrock Inc | 2025-06-30 | 3.8 M |
Krystal Fundamentals
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0891 | ||||
| Profit Margin | 0.53 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 6.51 B | ||||
| Shares Outstanding | 29 M | ||||
| Shares Owned By Insiders | 11.65 % | ||||
| Shares Owned By Institutions | 99.28 % | ||||
| Number Of Shares Shorted | 2.72 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 6.36 X | ||||
| Price To Sales | 19.38 X | ||||
| Revenue | 290.51 M | ||||
| Gross Profit | 351.76 M | ||||
| EBITDA | 109.91 M | ||||
| Net Income | 89.16 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 7.26 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 39.26 X | ||||
| Cash Flow From Operations | 123.42 M | ||||
| Short Ratio | 9.30 X | ||||
| Earnings Per Share | 6.66 X | ||||
| Target Price | 244.4 | ||||
| Number Of Employees | 275 | ||||
| Beta | 0.46 | ||||
| Market Capitalization | 7.23 B | ||||
| Total Asset | 1.06 B | ||||
| Retained Earnings | (180.67 M) | ||||
| Working Capital | 640.05 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
| Net Asset | 1.06 B |
About Krystal Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.